Key Points
- CEO Zhenya Lindgardt sold 22,639 shares on March 10 at $1.90 and 2,973 shares on March 11 at $2.04, totaling 25,612 shares for roughly $49,000 and reducing her stake by about 3%, as disclosed in an SEC filing.
- A broader pattern of insider selling occurred the same week—including CFO Austin Aerts and several other executives—which may weigh on investor sentiment for the small-cap biotech.
- Sera shares trade around $2.10
Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CFO Austin Aerts sold 6,069 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total value of $11,531.10. Following the transaction, the chief financial officer owned 265,471 shares of the company's stock, valued at $504,394.90. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Austin Aerts also recently made the following trade(s):
- On Wednesday, March 11th, Austin Aerts sold 1,019 shares of Sera Prognostics stock. The stock was sold at an average price of $2.04, for a total transaction of $2,078.76.
- On Monday, March 9th, Austin Aerts sold 674 shares of Sera Prognostics stock. The shares were sold at an average price of $1.96, for a total transaction of $1,321.04.
Sera Prognostics Stock Performance
SERA stock traded up $0.13 during trading on Friday, hitting $2.12. 26,392 shares of the company's stock traded hands, compared to its average volume of 56,926. Sera Prognostics, Inc. has a 52 week low of $1.37 and a 52 week high of $4.20. The stock has a market capitalization of $81.82 million, a price-to-earnings ratio of -2.75 and a beta of 1.01. The business has a fifty day simple moving average of $2.76 and a 200 day simple moving average of $3.05.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Sera Prognostics in a research note on Monday, December 29th. Jefferies Financial Group raised shares of Sera Prognostics to a "strong-buy" rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $5.00.
Check Out Our Latest Analysis on Sera Prognostics
Institutional Trading of Sera Prognostics
A number of hedge funds and other institutional investors have recently bought and sold shares of SERA. Riverview Capital Advisers LLC bought a new position in shares of Sera Prognostics in the second quarter worth about $35,000. Qube Research & Technologies Ltd purchased a new stake in Sera Prognostics in the 2nd quarter valued at about $92,000. Captrust Financial Advisors boosted its position in Sera Prognostics by 20.0% in the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company's stock valued at $1,668,000 after buying an additional 100,366 shares during the period. Corient Private Wealth LLC grew its stake in Sera Prognostics by 73.9% in the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company's stock worth $277,000 after acquiring an additional 42,500 shares in the last quarter. Finally, Birch Hill Investment Advisors LLC purchased a new position in shares of Sera Prognostics during the third quarter worth approximately $84,000. Hedge funds and other institutional investors own 54.64% of the company's stock.
Key Stories Impacting Sera Prognostics
Here are the key news stories impacting Sera Prognostics this week:
- Neutral Sentiment: Coverage piece contrasting Sera and Revvity — a recent article compares SERA to Revvity (RVTY), which may influence investor attention or comparisons across healthcare peers but contains no company-specific fundamental disclosure. Contrasting Sera Prognostics (NASDAQ:SERA) and Revvity (NYSE:RVTY)
- Negative Sentiment: CEO Zhenya Lindgardt sold a total of 25,612 shares across filings (22,639 shares at $1.90 on Mar 10 and 2,973 shares at $2.04 on Mar 11), raising roughly $49k; the filings show a near 3% and 0.4% reduction in holdings respectively. Significant CEO selling can weigh on sentiment for a small-cap biotech. SEC Filing - Lindgardt Sales
- Negative Sentiment: CFO Austin Aerts sold 7,088 shares across two trades (6,069 at $1.90 and 1,019 at $2.04), totaling roughly $13.6k and reducing his stake ~2.2% and 0.38% in filings. Insider sales by senior finance officers can signal near-term liquidity-taking and may be viewed unfavorably in thinly traded names. SEC Filing - Aerts Sales
- Negative Sentiment: Other insiders (General Counsel Benjamin Jackson; John J. Boniface; Paul Kearney; Robert Gardner Harrison) executed small sales on Mar 11 (combined ~4,656 shares, ~ $9.5k). While each sale is modest, the broad pattern of multiple insiders selling within a short window can amplify investor concern about management conviction. SEC filings: Jackson Jackson Filing, Boniface Boniface Filing, Kearney Kearney Filing, Harrison Harrison Filing
Sera Prognostics Company Profile
(
Get Free Report)
Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company's flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman's risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.
Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
